Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Introduction Major depressive disorder (MDD) is a debilitating disorder with increasing prevalence globally. Despite the development of novel treatments for MDD, many patients present with treatment resistant depression (TRD), identified by treatment non-response following one or more adequate trials of an antidepressant. Rapastinel may prove to be a viable treatment for TRD; it has the potential to produce a rapid antidepressant response without serious adverse events and improve functional symptoms. Areas covered: We review the efficacy of rapastinel via completed and on-going clinical trials. The online databases Pubmed, clinicaltrials.gov and clinicaltrialsregister.eu were searched for rapastinel (GLYX-13) treatment in subjects with MDD. Nine clinical trials were identified. Expert opinion: Rapastinel is a novel and potentially transformative treatment for individuals with TRD. There is a limited number of clinical studies so far, but this compound has the potential to provide rapid, reliable and robust antidepressant effects without psychotomimetic and other unwanted side effects. Alternative formulations such as the oral formulation, provide the opportunity for rapastinel to be administered less frequently, i.e. once weekly. Furthermore, the beneficial effects on measures of cognition and suicidality so far, represent a tremendous advantage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on safety and efficacy data obtained in phase I and II trials [164], rapastinel is not associated with ketamine-like dissociation and was granted fast track status and later breakthrough therapy designation for MDD in 2016 [161].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [161]
In the citing paper
“Preclinical evidence suggests that rapastinel may enhance dendritic complexity and long-term potentiation via bidirectional modulation of NMDA signal transduction [161,162,163].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [161]
In the citing paper
“Based on safety and efficacy data obtained in phase I and II trials [164], rapastinel is not associated with ketamine-like dissociation and was granted fast track status and later breakthrough therapy designation for MDD in 2016 [161].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [161]
In the citing paper
“Rapastinel (GLYX-13) is a small polypeptide that acts as a partial agonist at the glycine site of NMDA receptors [161].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [161]
In the citing paper
“However, during more rigorous phase III RCTs, IV rapastinel failed to separate from placebo as an adjunctive strategy and monotherapy (NCT02943564 and NCT03675776, respectively), and the drug’s AD development was discontinued, terminating future trials [161].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [161]
Citations
Cites
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“For example, wherein administration of N-methyl-D-aspartate (NMDA) receptor antagonists reduced depression like symptoms in rodents [15].”
BackgroundFerrari, A. J., Somerville, A. J., Baxter, A. J., Norman, R., Patten, S. B., Vos, T., & Whiteford, H. A. (2013) · Psychological Medicine · doi:10.1017/s0033291712001511 · Cited by 1,230 · cited 1×
“It has been suggested that the prevalence of MDD has increased over time, wherein this is underscored by the two-fold increase in antidepressant medication prescription observed in the United States between 1996 and 2005 [2,3].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730 · cited 1×
“It has been suggested that the prevalence of MDD has increased over time, wherein this is underscored by the two-fold increase in antidepressant medication prescription observed in the United States between 1996 and 2005 [2,3].”
Background(1997) · PubMed · Cited by 727
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Suicidal risk during treatment with clozapine: a meta-analysis
Hennen, J., & Baldessarini, R. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.015 · Cited by 287
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284 · cited 1×
“The antidepressant effects observed without the hazards of psychotomimetic and other toxicity effects are in accordance with the preclinical studies with rapastinel wherein behavioural and/or anatomical evidence of glutamatergic toxicity were not observed [29].”
ResultThe use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252 · cited 1×
“longer for optimal antidepressant relief which can prolong morbidity, suicide risk, and functional impairment [11].”
BackgroundDuman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
Lithium and suicide in mood disorders: Updated meta‐review of the scientific literature
Smith, K. A., & Cipriani, A. (2017) · Bipolar Disorders · doi:10.1111/bdi.12543 · Cited by 247 · cited 1×
“Although clozapine is FDA approved for suicidality in psychotic disorders, and lithium has demonstrated anti-suicide effects largely in observational studies, relatively few treatments have been primarily studied and/ or demonstrated to be effective for measures of suicidality in MDD or BD [12,13].”
BackgroundWidman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
PRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193
Lepack, A. E., Bang, E., Lee, B., Dwyer, J. M., & Duman, R. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.011 · Cited by 174 · cited 3×
“Brain-derived neurotrophic factor (BDNF) has also been identified as an important component in the mechanism of action of rapastinel such that when an anti-BDNF antibody is used in the medial prefrontal cortex, the antidepressant behaviour of rapastinel is blocked, additionally, increases in BDNF following rapastinel…”
BackgroundSheehan, D. V., Harnett-Sheehan, K., Spann, M. E., Thompson, H. F., & Prakash, A. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328341bb5f · Cited by 124
Koike, H., Iijima, M., & Chaki, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.034 · Cited by 114 · cited 1×
“Lepack, Bang, and Lee (2016) have demonstrated in vitro that GLYX-13 increased levels of BDNF-mTORC1 pathway signaling components phospho-ERK and phosphor-S6K in a dose dependent manner [26].”
BackgroundYang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91 · cited 1×
“Findings from animal/in vitro models Upon completion of tasks such as the forced swim test, female urine sniffing test, tail suspension test, and the novelty suppressed feeding test, rodents who were given rapastinel demonstrated improved task behaviour [21,22].”
BackgroundBDNF Release and Signaling Are Required for the Antidepressant Actions of GLYX-13
Kato, T., Fogaça, M. V., Deyama, S., Li, X.-Y., Fukumoto, K., & Duman, R. S. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.220 · Cited by 88
Burgdorf, J., Zhang, X.-L., Weiss, C., Gross, A., Boikess, S. R., Kroes, R. A., Khan, M. A., Burch, R. M., Rex, C. S., Disterhoft, J. F., et al. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.004 · Cited by 88 · cited 2×
“increases in mature and stubby dendritic spines) where the increased complexity could be a result of a prolonged increase in long term potentiation following the administration of rapastinel [25,28].”
BackgroundTreating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84
Self-citationLu, Y., Wang, C., Xue, Z., Li, C., Zhang, J., Zhao, X., Liu, A., Wang, Q., & Zhou, W. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu110 · Cited by 75
Combination/augmentation strategies for improving the treatment of depression
Moret, C. (2005) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a798 · Cited by 70
Rajagopal, L., Burgdorf, J. S., Moskal, J. R., & Meltzer, H. Y. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.060 · Cited by 45
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43 · cited 1×
“De Sousa, Zanetti, Brunoni and Machado-Vieira (2015) have provided an in-depth report on relevant treatment-resistant strategies for MDD [10].”
BackgroundGibbons, A. S., Brooks, L., Scarr, E., & Dean, B. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.001 · Cited by 41
Wang, H. R., Woo, Y. S., Ahn, H. S., Ahn, I. M., Kim, H. J., & Bahk, W.-M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv023 · Cited by 31
Relationship of prenatal depression and comorbidities to infant outcomes
Flynn, H. A., McBride, N., Cely, A., Wang, Y., & DeCesare, J. (2015) · CNS Spectrums · doi:10.1017/s1092852914000716 · Cited by 29
Research works printed but not linked: 2
- Moret C, 2005, Neuropsychiatr Dis Treat, 1, 301
- Thase ME, 1997, J Clin Psychiatry, 58, 23
Cited by
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
An update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 70
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Based on safety and efficacy data obtained in phase I and II trials [164], rapastinel is not associated with ketamine-like dissociation and was granted fast track status and later breakthrough therapy designation for MDD in 2016 [161].”
BackgroundInfluentialZhu, Y., Wang, R., Fan, Z., Luo, D., Cai, G., Li, X., Han, J., Zhuo, L., Zhang, L., Zhang, H., et al. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01218-3 · Cited by 42
Metadata
- Authors
- Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S.
- Affiliations
- University Health Network (CA)
- Poznan University of Medical Sciences (PL)
- Corresponding author
- McIntyre, Roger S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2018-12-26
- Volume
- 28
- Issue
- 2
- Pages
- 113-119
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2905977615
- Cited by
- 30
- References
- 31
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 6
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- major depressive disorder, treatment-resistant depression, NMDA receptor modulators, antidepressant efficacy, rapid antidepressant response, suicidality, cognition, clinical trials
- MeSH terms
- Administration, Oral, Animals, Antidepressive Agents, Major Depressive Disorder, Drug Administration Schedule, Humans, Oligopeptides, Time Factors, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.